---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-026900"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:07:23.291973+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports Q3 2022 net loss of $22.3M for nine months; cash $50.4M sufficient beyond mid-2024

## Summary
- R&D expense $14.8M (nine months) vs $11.2M YoY; net loss $22.3M vs $13.1M.
- Cash $50.4M, sufficient beyond mid-2024; operating cash burn $20.4M.
- Three Phase 1/2 trials for Annamycin active; no cardiotoxicity in 42 subjects.
- WP1066 pediatric brain tumor trial enrolled final subject in Phase 1 at 8 mg/kg.
- WP1122 received FDA Orphan Drug for GBM; Phase 1a completed; WP1096 selected for NIH studies.

## SEC filing metadata
- accession: 0001437749-22-026900
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/0001437749-22-026900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/mbrx20221107_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-026900
- JSON: https://secwatch.observer/filing/0001437749-22-026900.json
- Plain text: https://secwatch.observer/filing/0001437749-22-026900.txt

## Key facts
- Earnings Releases
  Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended September 30, 2022 and provided a pipeline update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774922026900/0001437749-22-026900-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.